lino Biotech acquired by Miltenyi Biotec

The ETH spinoff lino Biotech announced yesterday that it was acquired by the German biomedical company Miltenyi Biotec, a global and established provider of products and services for biomedical research and therapy. In 2022, lino biotech participated in the Venture Leader Biotech program.

lino Biotech's founders: Dr. Volker Gatterdam, Dr. Mirko Stange, Dr. Andreas Frutiger, and Dr. Tilman Hoss

The biosensor startup lino Biotech was founded in 2020 and is the only provider of Focal Molography, a novel method for measuring molecular interactions in living cells or crude biological samples. The Zurich-based startup aimed to make cell therapies more cost-effective and accessible for a broader patient population by offering new quality control methods that every cell therapy manufacturer can use to improve their production and development process.

Yesterday, lino Biotech announced that it was acquired by the German biotech company Miltenyi Biotec at the end of February. Headquartered in Bergisch Gladbach, Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for over 30 years.

Under the terms of the transaction, Miltenyi Biotec will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds. The specific terms of the transaction were not disclosed. lino's headquarters in Zurich will be further expanded for research, chip, and application development.

"lino's innovative biosensor platform and Miltenyi's cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays," said Dr. Mirko Stange, CEO of lino Biotech.

lino Biotech was selected to take part in the Venture Leader Biotech program in 2022. The startup's co-founder Volker Gatterdam joined nine other biotech entrepreneurs on an investor and business roadshow in Boston and Cambridge. The application phase for Venture Leaders Biotech 2023 is open until March 19, 2023.